HealthDay News — For individuals with type 1 diabetes, liraglutide therapy does not affect the rate of gastric emptying during hypoglycemia, according to a study published in Diabetes, Obesity and Metabolism.
Christian Seerup Frandsen, MD, from the University of Copenhagen in Denmark, and colleagues examined the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide on counterregulatory responses and gastric emptying rate during hypoglycemia in individuals with type 1 diabetes in a 12-week randomized trial.
Twenty patients aged older than 18 years and with glycated hemoglobin ≥8% were randomly assigned to liraglutide once daily or placebo as add-on to insulin treatment. A hypoglycemic clamp was carried out followed by a liquid meal before and at the end of treatment.
The researchers observed no significant between-group differences in the changes in gastric emptying rates after 12 weeks of treatment (P =.96); no significant changes were seen from baseline whether assessed by area under the acetaminophen curve or time to peak. Similar between-group results were seen in secondary end points, including glycemic recovery, counterregulatory hormone responses, systolic blood pressure, and GLP-1 and pancreatic polypeptide responses. There was an increase in heart rate with liraglutide (69 ± 4 to 80 ± 5 beats/min; P =.02).
“Liraglutide does not compromise glycemic recovery, [gastric emptying] rate, or counterregulatory hormone responses in type 1 diabetes during hypoglycemia,” the researchers wrote.
Disclosures: Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.
- Frandsen CS, Dejgaard TF, Andersen HU, et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study. Diabetes Obes Metab. 2016 Nov 21. doi:10.1111/dom.12830 [Epub ahead of print].